Merck & Co., Inc. vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Merck & Co., Inc. trades at $133.64 (market cap $321.77B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $60.45. The key difference: Merck & Co., Inc. pays a 2.61% dividend while Vanguard Emerging Markets Stock Index Fund ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Vanguard Emerging Markets Stock Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| MRK | VWO | |
|---|---|---|
Market Cap | $321.77B | — |
Sector | Health | — |
52-Week High | $131.84 | $61.24 |
52-Week Low | $77.60 | $51.20 |
Enterprise Value | $368.53B | — |
Dividend Yield | 2.61% | — |
Signals from Pluang's Aura AI — not financial advice
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
VWO trades at $60.42, up 0.15% today, with a bullish technical signal driven by moving averages. The ETF shows strong institutional accumulation, with Barry Investment Advisors increasing holdings by 6.1% (SEC filing, August 10, 2026). RSI levels indicate mild overbought conditions, while support sits near $60.
Outlook remains positive due to record capital inflows into emerging markets and low 0.06% expense ratio. Risks include concentrated exposure to developing economies and China's economic volatility. The dividend yield of 2.4% offers income appeal amid global diversification trends.
Trailing returns across standard periods
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →